We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.20683 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myoclonus After Cardiac Arrest: Need for Standardization-A Systematic Review and Research Proposal on Terminology.
Crit Care Med
November 2024
Department of Neurology, Neurocritical Care and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University, Member of the European Reference Network EpiCARE, Salzburg, Austria.
Objectives: Although myoclonus less than or equal to 72 hours after cardiac arrest (CA) is often viewed as a single entity, there is considerable heterogeneity in its clinical and electrophysiology characteristics, and its strength of association with outcome. We reviewed definitions, electroencephalogram, and outcome of myoclonus post-CA to assess the need for consensus and the potential role of electroencephalogram for further research.
Data Sources: PubMed, Embase, and Cochrane databases.
Etomidate and its derivatives: time to say goodbye?
Br J Anaesth
January 2025
Universitätsmedizin Göttingen, Göttingen, Germany.
Etomidate, an intravenous hypnotic used for anaesthesia and critical care, is known for its undesirable side effects, including pain on injection, myoclonus, and adrenocortical depression. Despite its continued clinical use because of its haemodynamic stability and rapid onset and offset of effect, alternatives like propofol, ketamine, and remimazolam offer fewer drawbacks. Recent efforts to improve etomidate through chemical modifications, such as methoxyethyl etomidate hydrochloride (ET-26), have shown limited success, with persistent issues like involuntary muscle movements and adrenocortical suppression.
View Article and Find Full Text PDFRepetitive muscle silent periods in acute post-anoxic brain injury: A novel phenotype of negative myoclonus.
Clin Neurophysiol
January 2025
Epilepsy Center, Neurological Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Electronic address:
Article Synopsis
- A study reports a new type of negative myoclonus observed in three patients with acute post-anoxic brain injury (PABI).
- The researchers analyzed EEG and muscle recordings, revealing a pattern of whole body tonic posturing accompanied by brief periods of muscle relaxation in two out of the three patients.
- The findings suggest that this phenomenon can be identified using sEMG and may involve cortical or reticular brain regions, contributing to our understanding of brain recovery after oxygen deprivation.
Dexamethasone alleviates etomidate-induced myoclonus by reversing the inhibition of excitatory amino acid transporters.
Front Neurosci
June 2024
Department of Anesthesiology, Sichuan Integrative Medicine Hospital, Chengdu, China.
Background: Etomidate can induce myoclonus with an incidence of 50 ~ 85% during anesthesia induction. Dexamethasone, as a long-acting synthetic glucocorticoid, has neuroprotective effects. However, the effects of dexamethasone on the etomidate-induced myoclonus remain uncertain.
View Article and Find Full Text PDFConventional and novel anti-seizure medications reveal a particular role for GABA in a North Sea progressive myoclonus Epilepsy Drosophila model.
Epilepsy Res
July 2024
Expertise Center Movement Disorders Groningen, University Medical Center Groningen, University of Groningen, 30.001 AB51, Groningen 9700 RB, the Netherlands; Department of Biomedical Sciences (BMS), University Medical Center Groningen, University of Groningen, 30.001 FB32, Groningen 9700 AD, the Netherlands.
Objective: North Sea Progressive Myoclonus Epilepsy (NS-PME) is a rare genetic disorder characterized by ataxia, myoclonus and seizures with a progressive course. Although the cause of NS-PME is known, namely a homozygous mutation in the GOSR2 gene (c.430 G>T; p.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!